<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-026845
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050824
<FILING-DATE>20050824
<DATE-OF-FILING-DATE-CHANGE>20050824
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051044778
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v024663_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of August 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 297pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 297pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Date:
                August 24, 2005</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td>&#160;</td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%"><font size="2">Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  closes ADR PIPE after raising US$4.2m</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="15%">&#160;</td>
              <td align="left" valign="top" width="62%">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v024663_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><img src="v024663_ex99-1logo.jpg" alt=""></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong>ASX/MEDIA
                RELEASE</strong>&#160;</font></td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Arial">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&#160;<strong>23</strong><sup><strong>rd</strong></sup><strong>
                  August 2005</strong></font></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="100%" style="BORDER-BOTTOM: #ffffff thin solid">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Arial"><strong>pSivida
                  closes ADR PIPE after raising US$4.2m</strong>&#160;</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="100%">
                <hr style="COLOR: #000000" align="center" noshade size="1" width="100%">
                &#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Global
        nanotechnology company pSivida Limited <strong>(ASX:PSD, NASDAQ:PSDV,
        Xetra:PSI)</strong> is pleased to announce that it has raised US$4.2m (AU$5.6m)
        before costs via the private placement of 650,000 American Depository Receipts
        (ADRs) to predominantly US investors at US$6.50 each (AU$8.61). Each ADR
        represents 10 ordinary shares.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">New
        York based
        securities dealers placed the ADRs in an offering which was structured as
        a PIPE
        (Private Investment in Public Equity). The ADR&#8217;s have an attached 1 for 10, 3
        year warrant exercisable for US$12.50 per ADR. The ADRs are expected
        to&#160;become tradable on NASDAQ upon filing of a registration statement
        by
        pSivida with the Securities and Exchange Commission which is expected to
        take up
        to 120 days.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Mr.
        Gavin Rezos,
        Managing Director of pSivida said, &#8220;The funding will be utilized to further our
        expansion into the United States, the world&#8217;s largest healthcare and financial
        market following the recent appointments of two US based Non-executive Directors
        to the pSivida Board, Dr. David J Mazzo, President and CEO of Chugai Pharma
        USA
        and Mr. Michael Rogers, CFO of Indevus Pharmaceuticals Limited and the inclusion
        of our ADRs in the NASDAQ Health Care Index.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">This
        announcement
        does not constitute an offer of any securities for sale or the solicitation
        of
        an offer to buy any securities.&#160; The securities offered will not be
        or have
        not been registered under the U.S. Securities Act of 1933, as amended, and
        may
        not be offered or sold in the United States absent registration or an applicable
        exemption from registration requirements.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Arial"><strong>-ENDS-</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Arial"><strong>Released
        by:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Tel:
                  + 61 8
                  9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">brianl@psivida.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Beverley
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Martin
                  E.
                  Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Tel:
                  +1 (312)
                  9 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">bjedynak@janispr.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong>UK
                  &amp; Europe Public</strong>&#160;<strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Mark
                  Swallow,
                  PhD / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Citigate
                  Dewe
                  Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Tel:
                  +44
                  (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">mark.swallow@citigatedr.co.uk</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">pSivida
        is a global
        nanotechnology company committed to the biomedical sector and the development
        of
        products in healthcare. The company&#8217;s focus is the development and
        commercialisation of a modified form of silicon (porosified or nano-structured
        silicon) known as BioSilicon&#8482;. As a new and exciting biocompatible material,
        BioSilicon&#8482; offers multiple potential applications across the high growth
        healthcare sector, including controlled release drug delivery, targeted cancer
        therapies (including brachytherapy and localized chemotherapy), tissue
        engineering and orthopedics. Potential diagnostics applications are being
        developed through its subsidiary AION Diagnostics Limited. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">pSivida
        owns the
        intellectual property rights to BioSilicon&#8482; for use in or on humans and animals.
        The IP portfolio consists of 26 patent families, 29 granted patents and over
        80
        patent applications. The core patent, which recognises BioSilicon&#8482; as a
        biomaterial was granted in the UK in 2000 and in the US in 2001. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">pSivida
        is listed
        on NASDAQ (<strong>PSDV</strong>), the Australian Stock Exchange
        (<strong>PSD</strong>) and in Germany on the Frankfurt Stock Exchange on the
        XETRA system (<strong>German</strong>&#160;<strong>Symbol: PSI. Securities Code
        (WKN) 358705</strong>). pSivida&#8217;s shares also trade in the United Kingdom on the
        OFEX International Market Service (IMS) under the ticker symbol
<strong>PSD</strong>. pSivida is a founding member of the NASDAQ Health Care
        Index and the Merrill Lynch Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">The
        Company&#8217;s
        strategic partner and largest shareholder is the QinetiQ group, the largest
        science and technology company in Europe. QinetiQ is the former UK government
        Defence Evaluation Research Agency and was instrumental in discovering
        BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ having access to
        its cutting edge research and development facilities. For more information
        on
        QinetiQ visit <u>www.qinetiq.com</u>.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">For
        more
        information visit <u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Arial">This
        document
        contains forward-looking statements that involve risks and uncertainties.
        Although we believe that the expectations reflected in such forward-looking
        statements are reasonable at this time, we can give no assurance that such
        expectations will prove to be correct. Given these uncertainties, readers
        are
        cautioned not to place undue reliance on such forward-looking statements.
        Actual
        results could differ materially from those anticipated in these forward-looking
        statements due to many important factors including: our failure to develop
        applications for BioSilicon<sup>TM</sup> due to regulatory, scientific or other
        issues and our inability to develop existing or proposed products. Other
        reasons
        are contained in cautionary statements in the Registration Statement on Form
        20-F filed with the U.S. Securities and Exchange Commission, including, without
        limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to
        update any oral or written forward-looking statements that may be made by
        or on
        behalf of pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v024663_ex99-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v024663_ex99-1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.P"_`P$1``(1`0,1`?_$`+0```("`@,!`0``````
M```````(!PD&"@(#!`4!`0`!!`,!`0``````````````!`4&!P$#"`()$```
M!@$#`@0$!`4`"P`````!`@,$!08'`!$((1(Q$Q0)02(5"E$C%A=Q@9$R&&&A
MP4)2<B0V)QDI$0`!`@0$`@<%!@,$"P`````!`@,`$00%(3$2!D$'46%Q@2(3
M"/"1,A05H;'!0B,ST6()X7)$%E*"0V.S)#0E-3<8_]H`#`,!``(1`Q$`/P#?
MXT00:((-8F#E!!OK)PS@@W#1!"3\IN=>!>(K6.8Y$G'D]DBU*$;X_P`(X]CU
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MDIM\5`4DNTOF-UE=P,7M$NQQ]+M.24!*I\)]?3W3[1TPT6MBOLW,UFRT=PJJ
MRW+MKCS[3Q2H-*"DI:42$@I*QJT@F1DJ0P,7[)]NVY?CU$?B/0-M_P"`:;4J
M29Z>F+EE'/7J"#1!!H@@UB8RXP0:S!!HZN,$&B"#1!!N'XZ.N"#1!!H@@WT=
M7&"#1!!H@@T01UJ>`#OML;Q_#H/41^`:\+E@2<`>DB,@RR$YPN>2\R3^-)9Z
M*^-969J;)%%P>SMYZ*9^I,JD"CI!HQ>'(NX49F#J0NYC;=P=`'7,'-SG[?\`
ME#=W%UNU:ZJV4RV%JN"*AMM!41XP$KQ.E/Y99XX#&'RW65-Q9/E.`U)R1@2<
M<9"8R$SW1(%;R=6KA15;S62.9=BW:O%E8M!N;ZJ5VR3,HYB19F$1"2[@`"%'
MY3[@("("`ZL+:W-[:>]^7[O,3:'FUE`VTM1IVTGYCS$`E3);R\T_DS!F"#*$
M;EO>:J12N2`4<SE+I/?F(@&1YD56(<>AEL=WJ(=BF0X-9)DQ8KBFH&Y3^4Y6
M((IF$!#<-P[@$/'7-]\]>&RMNU)M^Y+!?J&L")A+R$)61.6`5B0>G+W0[L;6
MJ7"/)6B6>7]L8#D7,UYY!4]6@X&GKKA"S6!^WB0RZECR%R,C5FSHABKJMX][
M,,8MF^[#%$KA453-O'R]]A":\L_6#MGF1>F+9MS;=]?IW'@TI[RTEAF?%Q0P
ME*1EG*1R(AKO6U;DJW/(HZY-*_(C6D`KG_*%',=8/9$68MXT<;N!;XEK40LV
M>N4%_4(M9LU9+DT+1EVUNW!BMWCDEEFU7#.C5U=PN8B;)CY"7ECY8]Y2[ZG?
M/?U+[,Y/+I;5=V55NX*HI134-.$AQ2%*"0IYU0(0-1`3JQ,L`9&43V/ROHK8
MZNXL:JJ[+'ZM94J"W3*9D"9:4C@E.E(X`0Q]XY..<8XFM.3+KC6=0DT',?"X
MRHL.]8V*R9;N<^4S6K5*J)Q93>>]EI50B:BO5-N@"KE39)(Y@DG*#?6\N8E*
M_5[GV\]MUE"QY"GWD.^<@B>I)02)2P!!D>$/6XW*2P4:JAIPU3P`"4)'B4LX
M)2D=))DL'X1B<(PS@[Q6M&'&>0\WYRD(ZR\L.1\VUN6;IR.5]=$UHC)(4:GB
M6EN3[@E2\>19B-4O*[4G3DIUP#82;7+4U;;@#*!)*9=YEB>_K)[9"(=M+;]9
M:$OW6\J2O<5<=;Q29I0/R--D_P"S:3)(D$@F:M(),/Z@0"%$`\1'<W\1Z[?R
M`=(T`B9X$Q+D@`2$=VO<9C@<0`H[[>`^/\!'^.O"R,$DRG[X])$S$.77.N,\
M>O@CK'9DDY`I0,:*8-7,I((E/OV"Y19IJB@!BAN`&$!$-4-S"]2/)_E;<#:]
MTW=(N29:F&D*?<1/":]$]/82,(<Z2SW"M,FD"1GB<)RCUT;-N-<CNC,:K8$'
M,FG\YHMZW<QTD=(`ZK(M7J:*BY$_]X2=W;\=M+N77J$Y1\T:I5%LVYMNW20(
M:<2IIU8_E2L`J[IQYJK774@)='A&<N$9Q;+"UJE=F;$^07<-(:/<2#A%N`"L
MJDV3%0Z:/<)0\T2EZ;B&K)W=N6DVCMRLW)7`JI*-E;JP/B*4)*E`=<@0.N$+
M+9<<"!F8BO$V;X#+GUH\!#R\<:"!F+GZJ5N45B/`7,44/(66#\L&X@;<0ZCT
M\=5%R7]0.T.>WU!S:C%6T;<II*RZ!(^:2<)$@?`1(X\>,+[A;*BW>6A7PKZ1
M+VZ8G?704-<&B"$.YX\^L3^W[0ZED7+%;N]FB;G;3TV-:T5C&/9!O)%B5Y8[
MAXG*2,8@5H+5N)>\#F/W"`;;>"RBI'*]19:E,9Q#MZ;XLFPK<B\7TN?*J=\L
M:4E4B1,8=QB:N*?(ZG<M<"T'D%0(FPP=2R&TDGL1%VENS:SK5*,F9"$6*^08
M/'[1,QW,:<Q0(J<.T0WZ[AK2^RJG=+2_B$/&W[[0[FM#%\MI4:.H1J3J$C(]
M(X80PHB4!#<0WVZ?U`/#_2(ZTSX0\RF>N$4G?<@X;5_D6WXI2^7V+7/;JV15
M';44]9M:RAK5-)(.(N*&91@SPI%72#E,P'%QY1>[J8-*Q;GE-><D301.(HO?
M.TVMP#:]15(3?"?VS/5E/HEEC#UE$=@[N@[!T_D&_P#0=(Y@'3QB6',RRCEK
M,8@T01TK"`%+OX=Y=^AAW\>FQ1`=:W"$IF2!CUG[HQ"^<C$T"4E%RHBU$6T^
MR[%G):@8$?/263,8I[JDM$I'5*/;\H`J)>A?CKF_U/,M/\OC5.4Z72R^F2RF
MB44:SH4I!KVG6$DI41,IU2/A(5(A]L4DUB=2_+3B9@RX'B)9Y=\+!Q4M,349
M',+::EF414H*.)<'TE(R<:E&1:#%95&2D7DJV<##)-$XTQ#*JIG!`I"=!V#I
MRA_3^N==1;SW7LE*S]-;0A]`*D*.I+H:G-L!LDI(!*!+`RPE#MO!VFIZ5%8\
MM+=.%8K,@`F4R3EA,0MN4>0^,.4;6HY;PY*2$[CYZA;ZS"V1XS48H64U/N$M
M"/9V&(MLLXK[]^U4,S7,!162`#]I=]M0+^I$SY7,FQ`I`6;+XL)?XIX=^&$S
MPPA)RQO]!N"TFY6U8=H_-6EM:A\12=)()S3AX>&4/SPM`/VEDS;!N:Z2@&'8
M-Q#T$/T$?B'S#_771/\`3P_]*UQX_P"8'QW"FI2!V3)]YZ8W[M2E-T3I`$VI
M]\U8]O7"N9*DCR?(._O5UD5"Q`GBF"3ES4")((-&S9J)2M[H)XQ5+S5%3"4I
M3*%./<``&XZY"YK5]1>O55N6MJ27FJ$E#6HT<DI2TVD)T7%MYA0!4KPI0%34
M5)(Q,/%O#?T9IHR0H@XC`F>/4>\=\6(5W'M8<_H&U/XIL^EZM7TD:V=PBP,V
MKR\G'II2<A$M6*2<<TE'S<?(.X0*&S?=-,03,8#?8[9M(BAVG;:-`2E#5&V`
M`EI`'AG@EE*&DC')M*4=`BO:QMM=45+2%+2LD$B9!R)!,R"1F8E(I"%_M(4O
M_*4`\?'P#4E(!Q.<:\XK-YN^ZAQSX&9'Q_C#,<%E*4L.1JW^J8):AUZ(EXQ&
M.+8%*X)9)Q(V*&,@Y*_3$P@"9R@EU$WPTX4MOJ*MM3K,M"3(S]\5]O#F5MK9
M%?2VV^K6AVKQ00)I^+3B>$CTX0I^<?N#N#F',I/<:1"61LO(0K\\9:KICAC"
M/JK#O$#%(^;Q3F1EV#FRJ1JI3$6,T**'>4034/I0+'6%'BP5+V_C$2W#Z@]@
MV*YBUNK6_EJ<:3J0DSE(J&9G@0)D<8MUHF9Z)FC"D/G#$E@;6RDVREN[54)I
MH53RGJ`,W)R$6;G'S4'C1TW.@N@IL=)8AB&#<!U"=X5=38=LW&X4R2:VEH:A
MY&9\;;*U)PXX@1<^WJ^@OZ::XV]P+M[VD@B6()E%:.#:C!Y9R2LTO<J\5"18
MR,P?L?)M'\Y,F.DH#(KI0IMAV<'.)2_.8I0*'AKX4^G38^V.=?.!VW<S:UPI
M=;??T%S2Y5/#)`<4<"?BEF=,DRBV+C75%!1>=1-@*T#(2S,CEC@.N)QM/%>[
MU^_PDAB)99M%$(A+-)29E$T!KDFW7[#,W#A),7CQ%;H<H%3$3)]Q#".^NB]Y
M>BG?NU>;-#=.2#KC=FU(J$/ON%LTCB58MJ<0E15X9@22J844JG(S9J7<;"Z%
M7SR4ES$$*Q)X83SGUF'JN#B/8T&8<W9B63CF\`LK96;0JBJ;I)%J'U%)N0RK
M<ZB:P]P$^8H[#KZ0[NJ:"AY=5-1OVG-72,4"C6H9&H.!+?ZVF:FR=0U2Q!Q$
M11A"U5A^3(!*O#/[!T1#?'VQXAG@M`8FJ3NN@T"/&:3<M3-/7`HF\%D"8&D'
MPJ"F)#@/4O\`=X:HWTM[JY&;F^JCDM:*FTTS2F/F?,!`6HAW0?WWIE/B$R>,
M.E\^JH+9KUZR!U8=0P$*7Q?]W7C)RIY$RG&"E0N6JQE*+;W4Z[2^UF'AHU1U
M1'?IK#%HN&5EE'(R:'EG4(3R0`R29A$2[:[)5;WVV/FRG]/#VSBEMN\T]K[H
MW$_M6A-0B[,!04EQ&C%!DK'\>,?=YM>ZYQMX&7ZGXSR[&9,GK5=*PK;HQK08
M")G46L5]85@VI))5[/0ZB#IZ_;J`B0I3@8I!$3!K6Q1.53?FH^%/MCC&[>7,
MW;>QKE2VR]%XU5:1Y80C5B2!+WD>^,#]S?-_"*FX$P]>.<>$K#E+'UOM4>\I
ME52@"R<S7+)(U-62]5+1Y;1!ILW*$4L=LJ4'"Q2J]`*/]VMU`Q5K>4FE,E@9
M@R_$0FYF7O9-MVXS6[YI2_97'DA"5)U244%0*D]6/9#6\"+9@2^\3\3VWC'2
M9'&>#9B-F5*'2I-I].>03!O8I9G().&A969*B+F62<+!LY4W!0!Z#T!/6!Y3
MA2X0IS*<2/9=98:W;%)5[;:\FS.LS;3*6E,SD.'\(KKR]]P-P?Q%FN8Q`X:9
M+N<56)U:L6O*-/B(B1ID;+LEC-I,(T'$TWD[`SAW:1TEUVQ"E%1,X)`KMN*U
MJSU3E/YZ92]O;+LBN[KZ@.7]EW$NPNK>6XVL(6XA.M"53$Q,9RGC*<I&>(B@
MF4R70\R^_ICO)^,;-$W7'MVY+XAG:S98=05XZ6C7,1!$(NAYJ::J:B2R9TE"
M'*51%4AB&`#`(:?"P]3VB3N"@I('3F/LCGVLNMIOGJ+I+G:GD5%(X^@)6@@I
MP94%)PXS`G.-U/D1R4PUQ0Q?-9?SI<FM/ID*NFT!PN4SF2FI=<ROH(*NQ2.[
MR9FW_EB":"0";8!,82D*8P12FIGZI?ETZ=2\3V".U-P;@M&V+:N\WM]#%"DY
MDC.>``XDY`"*3VWW*_"]Q8BQ2V,,_,:X=8"#:#0=76410.IY8/7$"C9SR`-P
M(('$"F,H!?`N_33F;#5K3K40#T81237J:Y;A\,DU/EE4M1;.GWY_9%U-?Y.8
M.MG'9WRFKE\836#(Z@V+)SV\1@.G+9M4ZC&/I:S.W+$A1D4GD&UBW!7302`X
M352,GV]P;:9W*5U%0&?SE0$L>)E%WM7ZRU-B.Y*=Y*K*EI3JE@X!"$E2B3U`
M&&'.`&V`2B;K\!VVZ#U$=P';X?SUY*0H2.4.\1OE5D1[1["!%T6CEJS!Z@Y<
MOXJ,1159*%<&\V1FFDA%L"'2(8#*JI"!0,/4/$*_YH;?N>X]CU]LLB"N\%G6
MPD%H%3C9"TI"GF7VTZ].@E32I`X2,E!=0U#3#R7*C2:5)\05D)X3,B,!.>?O
MRBG_`"9C#&N4G%QQ3GYU*HXKRBYAF][:U"W,SS:1JS/PE@3CYA_7FC3LB)![
M&>0]1(T("C1<X%`1ZA\J>4'-$\@?4357G>Q;I;1>V5L5@#K-6[3+40I"W?(:
M9#>AT`J"&1X3X1@3$CW;MJBWIMLV.K0I5)(%)2K0EQ`,RB8))2K(@@`C`F)"
MY"H8PCG6.:WA]"KQ]%J6/V<#"P]101:P4(S9O'*;6,9LT"$*U\E``$2F*!S;
M]QA$PB(M'KPW_M3F!OZRW3:-PI[C2-VC2I;2IZ5&H=7I.1!D09$"71"[:]N^
MDVPVTLEJ@0H!M"0`D`2&,OP,,#QHRQ1,<8@EAM,ZU:/26J5=HPZ9RK2SU,["
M+!OZ5D7=4WGJ(F*43=I`V$1$`#5P>CGG9RUY3\BKD_O.Y-,5:;T\ZFG3XZAQ
M)IZ5(\MH9ZE`@$D)F#CA'G<MMK:ZXI73()0&I3X3F>_(]O5$3XM:6&_9!L-@
MCR(.7-QEU9!XV9V.MM9.(AU'YEW#A]$RD1-KK%12$@$[`2.?M#81`=]4_P`E
M:3<_-'F?=]WVYKYIJ\5R@O344;;S--YQ*EN,OT]6<&I!(0$G6#)4B"%=8\S2
M6YMM:$)4A..K$SE+"1Z>GOBU5BF1%FV13+VII)%3(78`V*0.T.@`!0W`/```
M`^'37VFI&FF:5MED$-(0D"8E@!+*0`[@.R*[<4I2RI1!43F,H]>E$>(THON?
M]PY/<<!*(@8,`36P@(AL`Y$E=_`?B`:ENW$A3#VK*?X1Q-ZK0GZQ:=0F#3N>
M\.0Y?NW\1^/&._:-QI9<;XCH=&G\?.L(R\//UV`8QU@6&UQ2#2T)2<XBC]4F
M`FCR?FJ^J55W53*8-NT-)+165!N>A:U%"B01G/HBP^<6U;*WR70Y14S+3U.U
M3K24I`EJ*`L8"?B!/?U3AH?MUYB0G?;M1BG[@R[*JYNRA`QB*QU%`2C')(*;
M,R(!S&*1O]0FG!^P/E#S!TV;F:0:UQIW3\LH%*TD3"DJ`$CT3GB<?QB1^G%Y
M]?+2E\PE3J'W0"2<`%F0'4!@!PX<(;_-'%.?@I%[;L7@9]%&<G>GKZ"AD)F&
M6W$XJ1"G<4SYNF?<2%(8KA/?8.\`#;X]^H#T6;CV]=:C?7)A*WK2E9<51MK4
MFIIE3U$T\S^HT,P`L.)`DE*CEUG:MPAUL4U:27)9R$O?,2GQG@>F/'A[E)9:
M]*1]2R@NI(P972+$\P]2.E/0B@*`W($F!BIJ.T$U!#SA.4%DB_,(B`#I!R"]
M9N]MKWYC8?-[S*NQ+=#!?=1HJJ11,@5GPZT)P20L)6)$E2CA&NZV&FJ$^?2@
M!S,2.!/6)?:(=_+ZR*^)KZH3<Y3UF242.4VX&36:=Y5""4WS$.3;80U](N>%
M13O<E-P5#*@6#9WE(5.84DH&E23Q!"ACQB*6UI2KHAIPC4E8!_$0J?!H`!'(
MINHF[H#J81,(=H2&P`(B(AX_#7$7]-V1M.ZER&H/4>,I?E?/"'[=?Z;J$HP3
M(?=&L3GU@GP=^X&JUX563A:;?LNT^_@X23%LW3JV;F:E9M)1,':FHV;SCMX!
M@`/[BB`CX:^N=/\`\]MU:$3+K9FHGB,\.R9&4?/B]E>S/4@S5)5H8KG$$DXI
M*7D:-,SD=:0<SB>Z.7+=BIS=]_>NXBV4D*K3<F8_QR_;I@99)I7L219;==Q.
M7<03(:5:NDSB&Y=S["&X#I/3%-+82M.#BC@>,N.?1C'K=Z5;V]1%)9IK<I+>
MM$P)A*-"?,49CA/2%=>&46._<T))I\5,"@F4I"FSBN8`((@4`&I20`!0`1`I
M>TH!L'3II#MV3E>`?A5G[C%D>II"5;%8F)CYYN79I('V0V?MGR[R`]E:B3D:
MJ9"0A\`9TF62Q!$IDGL:_P`@.VJI3%$#%.FND40$.H;:05:&V[D6TCP>:</]
M8Q,^62S3\H*!UO!:;8I0/6$J(,4(?;CX:QIF'DUF^?RC2JUD!6DX=9RE>97"
M'8V&+8S-MMR#*5E/I<F@X8+O5F)%$@4.F(D*J82[".X/M^<<I$H9944L*!P'
M5*.=O3+04=[W3=[A=FFZBK0R%!2T@G4M9U&1$L>/=*,-L&-J#B3[@.F4'&=9
MCJ738/EAC8T-6(1OZ:'BQE$(62?(Q[4#F(S:J/W:BA4R`":?<(%*4.FA*U.6
M0DXN:DS)Z)B-==;:&S^I>FI;:RAFD-0A92G`:E,J*B!B!,XF0&.,;,/N;^VO
M`>X1'X]/><^V/#%/P]^JYA1I&P$'+PSY[*I(I+628=SDG&MXWZ5',C$\PQA3
M*0YA$2[CI@MUP<HW2&0"Z01B)B1EA*8QRCIOF5RYM_,6A9I[E5/4U-3+4LA.
MD`G$`DJZ`3T9QK]>XY8/:)Q/PX8<5..@4_)7(RDGK9H?+%`K`2#I2=8/T"7*
M3NN32'282A[#'J.3"S:+2"!!.F4H%*4!!YH%75^K^9<F&9CJ$NS[.@810/-.
MOY1678JMG6@L/W]M"0@LHFI#B9:E..#`3XS5,XX'&&>]JN4>O?8M]P]@X<*K
M-(6D\OR1R*IA.1F1]Q^=/7:;<IC&!--9XH902@`!WF$?$=:JX?\`?&DG+S4?
M>(>>6:EGTWWELGPBV7(=WD/&-M!<XIE*8`,/SE#8H;B("`AU#\`WW_EJ/1UB
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M'><8KRY,8VJN+[=`Q-0;.VD=(0(R;E-\_<2)_4@^=-SB5=P90X)D11*';N/7
M7R$]8?)O9G)W>MMM6S6:FGI*VV^<I+KGF?J><XCP'"29)&&77$^V]<7J^E=*
MP%@&:M.8QGEB8E'CGB'%%NI0V:]ME%9I6V2,/'I&EWS%&03;-V*Z#)K'H*IF
M?+%%V;N*0AA[>H[:N[T>>F_E3S4Y?/;MWO2U57<F+LNG2D.E+(2AFG<DI*!(
MDE9)*E8Y<(07^_5="^AFF*4(6F8U"2CB1,`XY`82A_*K0ZE3&AF]5K<5"(K@
M4Z_T]JDBNY,!2@05W!MUE1(7P[S#X:^F.T.6VR=@-+9V3:J*VM.$%18;"%KD
M)`J5B3AG,X]$0]^L>J!^JHJZLACGA&9I%[$REVV[0VVW`?\`6'34[2G2D)SE
M",F>,I=4=FO4$:47W/W7E!QO*'4PX!F=@_'_`,B2W\M3';*"MAX)E/M'1'%'
MJM0I5VM*@)@4[I/4`L8GJAX/=UY1X!O/M$XYKU!RW0;K.7YS@R(@8:MV>)E)
MDZE<BD'UB4>0J#DTI'$A2Q*B;GU*2(I*&*4VQC``MUII7TW4%25!*5$D\,XL
M;F_NBP.\F`BGJV'5U#-.V@(6E14H:21@3*0![(G3[?V*M$![9TQ+13$HR]AR
M]EVP5)&016*UD/I[6#B$A.*9DU%$%I6%61`2F#<Q1`!Z#J)\TZR]T5FNE=M9
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M0%>%3:D@(<DG0"M!4DD9S!D\6)BJHZ8BXI(2`2)R)$Y2''C/LA\;0Q=L..;]
MG)]X2#3&::#WS`$#^:E$I`H4_<(G\PIOE$!Z]-?47=5NJV/2P_;+IJ;JT[40
MA>H^)*TTZ24GC,2EW1"4*;5?RM)P+G#MA>N#ARE;Y#W'^X\$4-@$>O;(#N.W
M@&P>/AKE3^FX1])W2GB:BC'?HJ(=]XH4A]O4,5)!'NBB_P"Y?PZO'R?%;D_$
M-E&\A&O9O%4NZ(/<DFNS>)7FEJN%R;`0Y%D9$$]S;B'0/#7UJVXZE7FTCA\"
MT2]N\X]D<,^IZTNTC5KWC1`ZZ1_0H@3\,]:%*_-\20D?WCW1%]O33;'GKF[R
M6Y>Y`2^KSM?K$JNM,%2%)LID/,UC,]EED/,,8$SA!13P`+XD(XV#QUB_::2D
M;HDD3SET=_OPAD]-S%7N;=UVWS=$*^:*=*53&G6LS6F72E(1CUX'.'7^YF.0
MW%7`I"%,02YT<)]ABF#Y@J4F8>T1``,38W0?#2?;B97$'@D8^XQ8/J9<"MB,
MJR2*]L>X*_"&Q]M*+>3GLJ46%CD3N'\OQ\SQ%,4$R"=5=X_?W]FV133#YE#J
M+J@4`#Q$=M-U?A="HY>83W:C$RY:-K>Y04#+8FXJU*`'22E4OOBA_P"V^RQC
MS%?)?/$!DBWURBN;CAF.:U]>VS+"O,7DG5K8@\F(E-[*.&S4'K=DL=82&.4>
MQ(VVXAIZW$E52AIY@%3>E6(!ZO;LCG;TQW"AL^YKM;[HZVQ6+:"0E:@F:D+5
MJ$YRP'7&"V?(%*RG]P35+MCBSPUTJ,MRPQNE$V2`>)/X:3/&MH2.>FCWZ0B@
M[10?M5$_-3$R9A(/:(AUU[;:6W8UE8D04G'^\!&FON5#>O4E35EI=2_3_-(0
M%)^$J2RH*`.1D<)C">$._P#<I<G<JUZVXBXM5NQR57QG:Z$ODF_DCW+IJ%P=
MK663KD3#RJS4Y%7=?A4HL[H[0![%ESE$Y3=I=)K!1-/-N//`DHQ`'?$X]3.[
M+I1.V[:]`\NGHJL:GEHF%:4JEC+'2)DJZ0)3E$?\P,%^VUQ#]J]]5L2W7%5_
MY%9GAL=K,+T6;A;MDVVN0EH2?L9XE&,4?JT&J,F*:I?*328(E*`)*F45$0T-
M.7&X7%'E$_+I7,C(2';V?9TYZ-V6#EMLGE*_36PTJ[W74J0AV8<?>62DS!$U
M"4R<9!,SED))]J$/_AS[D8!MO^BN6?Q#;?\`QS7WZ^&O-?/ZZT?]ZC[Q&WEC
M/_YQO2CE].N?_`=BY7W7N1V0\0X/I^',%%44Y&\N+^PP+B(R>Q%8,9XG;<+@
M4_S`D-?@5Q*0XB'EJN2*;AV;Z:J)I"WBXY\#:2KMD0`.^?XY1>',B_U]IL[-
MML@"MP7.H%,P.*-25%QXCBEI`)5V@9D0S?#+BO0^&N!*+@RBD!RG7&9GEMM#
MI(I)6]7J5*FO9KC+K%*07#N7D3&\ONW%)N5-(!$";ZTON^<X5])R&0'X1(-I
M;9H]HV!FRTNHI;$UK5\3CRL5N*/$J),S(8G*&I<.&Y47`J+II%12,HLH<Y"$
M12(`F.JJ=00333(0!$3"(``==:)`G2>,20.!)U?Z.,44\L^2$5G7+*U.XHG@
M,PS./X7Z%D')RTDHWP!B:2/)/%3-K;?&)'"=GL*:1MT8*"%X_<GW()DMC"7@
MCU;<A6=];NM6_M^7:FL/+*W6ORZEYQ:?FWW/F7E!BE;,]2U)(QD2`H%*58D:
M;1OQA\OV3:K/S][2O2MP332LS(GYKHPUIST#'*<IB'1X(XMKT#1I2WR5AF;[
M?U)F6B9"\V,$&@`U%)F\=,ZG4FJJL31Z^HX<;%;HF6=+%(!G+A8^^UC^DG='
M+^Z\O:ZGY<4"K5M*BN[K3;;JP7ZB3#$JE\3)"W!@!/A(0[7&UUM+4HJKJ\FJ
MN2FOW$F:4&9F$<`)B>'5/&+#4PV3(&^^Q"AO^.P!UUU>DZ@%#(B&_'CG'/68
M(-$$:4OW/@#_`)0<;3%W`W["3&QMMP)MD25-W!\!'_9J8;8\E#+SJP=>`!X=
MD<3^JI2OKEI0#G2N"7%4W):2.@Q8]-_;Y<,,X-\<Y2KT]DW#I+)2*7/7*FX[
M7@G%8F)%_`QCZ1=0Y9Z,DWM9/)K'.91-NH=`#G$R:9.@`T"\UC"E)5XL2!U>
MW7T19U7Z=]A;A%'=U(=I%?+M*<:9(#3AT)!!!'A/3H*2<29DQ>YA'#&/^/V+
M:5AS%U>_3E!Q_"HP5;B?.5=+I-@.LX>.7CQ416>2$B\<*.'"QMA575.;IOL#
M'4:G7OFG"2J60$_LB^[/:;?8;>S:+4@-V]E`2V!^4#@9Q@&1N+6/L@3"\[M*
M5N7?G\V1=08MA0DEREV!P]9/$5FI7`AMNHGV&-M\P#KD7FMZ->5O->\*W&^*
MJTWQY4W7*4ITKZ24+!0%*_,0-1B8T6XZNWH\M'CGQZ![93CQT'B=CNBS#2>4
M-+VB28."NV'UQ1J1HS=E$HE<E:1Z""+A9,2[E,L)P*/@&DG+3T3<J.6]Z;W$
MI59=KM3J"F34E`;;4/A(;;`2HIS&H''&/=3N2OJF%-%6D$2ZY=^7=#!6BMM+
M17)FM/A<)LI>.<,5SM-@7(DY)V',B=3O`52?#<!\`Z#X:ZAW3MJDW;MVLVW=
M"I-OJZ=31T?$E*DE)EUR.'"<,M/4%AY+V!5.<1KB/"M=P^6;"">S\C]?]'ZG
MZL+50R/HBK$3!#TC5J0I3@N/=W`(]`VU47)#T^[5Y#M5K6V*BMJ?J*FU+\_3
MX2T%A/P!($]9S$X5W"[+N!25ID499G[XB[FCP[QESFPJ^P3EA6SQ%95L\%:V
MDU4E6#2P1DQ7U%C,G4:O)L)-D4JJ+E5!8#(F[DE3``AXZZ-IJEVF6'6R-4I1
M`=W;5M6];([M^]!SY12DD%$P?"=0D1U_PC#N!OM_X@]ONAW*A8@D[C.HWNU)
MVV>G+RZC'TTLZ:Q:,5'L2K1$7%-2,&#=$PID%,QN]4XB;P#6:FK<K'-;\S+V
MPA#L?8=DY?6QRU6(*\IUS65*,R3*6/<)1SYW<!L6>X#0Z?C[+5BO=;AJ7;1N
M$8[HCR(823E^I%N8D[5Z:7BI=$S,$''?\I"'[P#YMNFL,5*Z51<:P)C9O?8E
MHW]:F[-?%N?*H>U^`RF0)"9':8F3BQQMJ?$W`]`X^T27L,[4\=,I)C"REK58
M.9YVC+2TA-.ADE8YE'LCG!Y(G`O8@0`(``("/76AYY;A+DCKG/[8=MM[=H=L
M66FL="I2J2F1H3JQ.GH]T5'Y>^W<X:Y5S3,Y50M65Z%`6J<7L-EQ?3GM=3K"
MDA(NC.Y9.!?R40[E:Y'R3DZBBB*9E?*,J;RC$#8`=VKW5,4AID!,CQ.8BIKS
MZ>>7]YOB[VZEYM3CFM;:%%*%J.9,I$3ZB.N9B9H3V0N(E/Y)8PY(X^=Y&H$C
MB.1H<C4<>5V1@?T$@I0&2+1D5XD_A'=A?*3*J/J'RQWHK+N#F/W%[M@3*N=4
MXP6G,4G&76)?PA[:Y+[-IMR4NYZ!"Z>LI-(;0C!$AJ&(EC/4<3C$V<_O;%P+
M[AT=4U\H.[=2[Q1$WC2JW^DK,"S#6'?N"N'\!(L)9F^C96'<NB`L4ARD426W
M.0X;CK%ON-31`^20`<P>/M[_`,7;F#RTVYS%I&V;R'&ZEDR0ZW(.!,YE(F")
M*X@@C(YR,)71OMU.#U4QW>ZG-R64KM<;M'L8U+)\O)5YI8J8U:2;.45/28IK
M#GKL:^D/0^G<.'#=VL+=4Y"&)OI2]?*UQQ*DR2!G+C^,0^V^G;E[;[8Y;EH=
M?<=``><5-QN7%&`"5$$B:0,##K<>/;+PWQJXK9RXC4RW9)F,=Y^B\A1%JEK$
M^@5[5$HY)HZM#FSP3QA`LHY%1O&+>:@*[=8I5R@)@,7<ND#E6ZM\/G]T$&?8
M0?PB:V/EQ8K%M*IV31K=-FJFWVUZCX@AY"D+D<\E&1Z857,7-_@O_FD>D\Q+
M0YPIEKA=DM];L#6.QM)HE0MU6R1C*(CWL@#]A%R+-T=<SY;\E8J2B2S4BB*@
MCYA0WM,U`8+C0*DK24F6/$<.[[H8;OO/9K6\5T&[JANANUJ?#M.ISP)6VZVE
M)TJ."YDD$<"F/N73WN^.\Y(C1.'V.,Q<T\J*G!E#U_%-'G8RJ&>F`0(K+7"?
MCD4V#(@B`J*$:G*)-_F#?66K8\MLN/D(:`F3.1E/HGJ^R-U5SBV]6/FCVLQ5
M7>XZY)2PV?+*B)D%]0#:=*9JD5#@!,D3Q^%XD<]^=4@VF_<'R:;`&!EW8O&_
M#KCI8%V#ZPLSD+Y+++>5HAR,G(LC"`&69-W*P#L)?R.H#L34L484*="7',@I
M0G[AEEV]QA,WMS>^\R'M\5"**RD@BAI5*2LID,'WP0I0SF$:.@ZA.+%X_A5@
M>MUZ#I=0@WM&H55;$:5NDTU5G!U:%*1(J"BS6+:,?SY1V!>YP]7,J\<'W,HJ
M81$=<J<U/33M'G)N$WK?MPO%4@?"P']-,WG\")>$XXD2*OS3B\[#4M;9M[5N
ML-.Q34S20`E"93'7T]\975N+V/J?*Q\Q!R=T06CGB,@DS-8EBQSE5#H0CUDB
MDBBZ1$#=0-ON'COMIDV3Z0N6O+^]L7S;-5>&:AET.Z!4J#3BDY!Q(`"APD>&
M$+:G<-;5`AP($YY3ECU?V0RI0V*`?@`!_0-=8`S$X8"23,YQ^ZS&(-$$5Q\T
MO:YXL<\KI4+WGQ#(:L]2:LXI\*--N:M89_1GDLXF52O6R<<\]2Y%ZN?93N*(
M$';;XZ64]>_2H+31&DF>4\H@>[>6FTM]5;%;N)A;U13)D@A:D2$]7Y2)X],/
M[5X!C5:]"5B+\_Z978>+@HTKHX*NBQ\0R1CV7J%P*45UO3-R]QQ`.XVX[==)
MEJ*E3)F3$X8::880RRG2A"0D=B0`/LC[^O$;(-$$&B"#1!!H@@T00:((-$$&
MB"#1!!H@@T00:((-$$4;^YI](_=JC_5O_5'_`-N)>F_SG_7'[H]_KW'=]&_1
M/3]'>'D>K_+]1YFWQTOIOVC^Y\)^'MX]73W166\I?4FY_P"7_A_Q\_,X_!+A
M#Y\(>W]L$_+_`,-_+V1[/\+_`#OV[[?S-O/]5_U7G[?\?S;[[]=](U=_?$FV
MK_T!_P#&?'_@?VN_^;IAU=>(D\&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:(
;(-$$&B"#1!!H@@T00:((-$$&B"#1!!H@C__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
